West Pharmaceutical Services, Inc. (WST)
West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.08 per share. This compares to earnings of $1.84 per share a year ago.
Curious about West Pharmaceutical (WST) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for West Pharmaceutical (WST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
West Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical Services, Inc. WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.
West Pharmaceutical Services (WST) Is Up 4.24% in One Week: What You Should Know
Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.
WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?
WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.
West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical Services, Inc. WST is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
West Pharma says operations recovering after cyberattack
West Pharmaceutical Services said on Friday its operations were steadily recovering after a cyberattack earlier this month disrupted manufacturing and logistics globally.
West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Bank of America Global Healthcare Conference 2026 Transcript
